KIR3DL2 and cancer: KIR2DL5 (CD158f), the most recently identified functional killer-cell immunoglobulin-like receptor, is expressed in NK and T lymphocytes and has gained interest in cancer immunotherapy with the identification of CD155 as its ligand [153], which is highly expressed in MIBC [154].